O’Melveny & Myers LLP advised the independent committee of ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, in a merger agreement to take the company private.
O’Melveny’s team was led by partners David Roberts, Paul Scrivano, and Ke Geng, and counsel Nima Amini.
Related Posts:
- None Found